加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.87
+US$0.0586 · +7.22%
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
收盘时
US$0.87
+US$0.0586 · +7.22%
盘后
US$0.82
−US$0.05 · -5.75%
10月13日 18:55 ET
盘中时间采用ET。市场数据可能有所延迟。
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
日内区间
当前US$0.87
52周区间
当前US$0.87
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
42
合理估值
情绪
51
多空交织
风险
69
高风险
动量
37
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
日内区间
当前US$0.87
52周区间
当前US$0.87
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（SGD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 31.92万 SGD | 6.95万 SGD | 50.91万 SGD | 36.56万 SGD | — |
| 销货成本 | 120.58万 SGD | 1.71万 SGD | 3736 SGD | 10.9万 SGD | 3501 SGD |
| 毛利 | −88.66万 SGD | 5.24万 SGD | 50.54万 SGD | −10.9万 SGD | 11.03万 SGD |
| 研究与开发 | 218.21万 SGD | 190.95万 SGD | 159.4万 SGD | 152.22万 SGD | 109.02万 SGD |
| 销售、一般及管理费用 | 144.18万 SGD | 126.57万 SGD | 49.05万 SGD | 59.65万 SGD | 58.85万 SGD |
| 营业费用 | 363.32万 SGD | 318.29万 SGD | 208.45万 SGD | 217.42万 SGD | 126.69万 SGD |
| 利息收入 | 12.19万 SGD | 31.77万 SGD | 28.15万 SGD | 2046 SGD | 3389 SGD |
| 利息支出 | 2.06万 SGD | 2.03万 SGD | 5.05万 SGD | 12.21万 SGD | 11.84万 SGD |
| 折旧和摊销 | 40.16万 SGD | 33.54万 SGD | 38.11万 SGD | 39.29万 SGD | 32.99万 SGD |
| 营业利润 | −451.98万 SGD | −313.05万 SGD | −157.92万 SGD | −228.32万 SGD | −115.63万 SGD |
| 净利润 | −391.68万 SGD | −251.67万 SGD | −414.42万 SGD | −305.55万 SGD | −207.37万 SGD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
